Leerink Partners Maintains Outperform on Abivax, Raises Price Target to $148
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Thomas Smith maintains Abivax (NASDAQ:ABVX) with a Outperform and raises the price target from $140 to $148.
Leerink Partners analyst Thomas Smith maintains Abivax (NASDAQ:ABVX) with a Outperform and raises the price target from $140 to $148.